Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2012 / Cilt: 20 - Sayı: 4

İntermitan klodikasyonu olan hastalarda yürümenin metabolik etkinliği azalır

The metabolic efficiency of walking is reduced in patients with intermittent claudication

Pages
774–779
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our study results suggest that oxygen cost of walking, preferred walking speed, Borg score, claudication pain scale score, initial claudication distance and MWD are objective parameters which can be used in monitoring the ambulatory limitation of PAD patients with IC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: We aimed to determine the differences in the preferred walking speed, oxygen cost of walking and their correlations, comparing the intermittent claudication (IC) questionnaire, claudication pain scale and Borg scores in the patients with IC and the healthy subjects.
📊
Key Findings & Data:Methods: Twelve healthy subjects (group 1) and 12 patients with IC (group 2) participated in our study, one healthy control subject and three patients with IC were excluded from the study because of exclusion criteria, and remain 20 participants were evaluated (n=11 in group 1, n=9 in group 2).
💡
Conclusion & Impact:Our study results suggest that oxygen cost of walking, preferred walking speed, Borg score, claudication pain scale score, initial claudication distance and MWD are objective parameters which can be used in monitoring the ambulatory limitation of PAD patients with IC.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: We aimed to determine the differences in the preferred walking speed, oxygen cost of walking and their correlations, comparing the intermittent claudication (IC) questionnaire, claudication pain scale and Borg scores in the patients with IC and the healthy subjects. Methods: Twelve healthy subjects (group 1) and 12 patients with IC (group 2) participated in our study, one healthy control subject and three patients with IC were excluded from the study because of exclusion criteria, and remain 20 participants were evaluated (n=11 in group 1, n=9 in group 2). The participants walked on a treadmill at pre-determined speeds for the measurements of oxygen cost of walking by indirect calorimetry method. The IC questionnaire was administered prior to the test. Results: The mean walking speed in group 1 was 77.8±11.4 m/min and 67.2±10.5 m/min in group 2 (p<0.05). The mean oxygen cost of the walking trial in healthy subjects was 0.14±0.02 mL/kg/m and 0.18±0.04 mL/kg/m in the patient group (p<0.05). In group 2, there was no correlation between the IC questionnaire score and oxygen cost, preferred walking speed, claudication pain scale score, and Borg score. The oxygen cost of walking was significantly correlated with the maximal walking distance (MWD) (p<0.05). There was a significant correlation between the initial claudication distance and Borg score and claudication pain scale score (p<0.001). Conclusion: The metabolic efficiency of gait and the preferred walking speed may be reduced in PAD patients. Our study results suggest that oxygen cost of walking, preferred walking speed, Borg score, claudication pain scale score, initial claudication distance and MWD are objective parameters which can be used in monitoring the ambulatory limitation of PAD patients with IC.

Özet

Amaç: Bu çalışmada intermitan klodikasyon (İK) olan ve sağlıklı bireylerin tercih ettikleri yürüme hızı, yürüme oksijen maliyeti açısından görülen farklar ve aralarındaki ilişki araştırıldı ve İK anketi, klodikasyon ağrı skalası ve Borg skorları karşılaştırıldı. Ça­lış­ma pla­nı: Çalışmamıza 12 sağlıklı birey (grup 1) ve İKli periferik damar hastalığı (PDH) olan 12 hasta (grup 2) katıldı, bir sağlıklı birey ve üç İKli hasta dışlanma kriterleri nedeniyle çalışmadan çıkarıldı ve kalan 20 katılımcı değerlendirildi (grup 1 n=11, grup 2 n=9). Katılımcılar, indirekt kalorimetri yöntemi ile yürüme oksijen maliyeti ölçümü için önceden belirlenen hızlarda koşu bandında yürütüldü. İntermitan klodikasyon anketi test öncesi uygulandı. Bulgular: Grup 1in ortalama yürüme hızı 77.8±11.4 m/dk., grup 2nin 67.2±10.5 m/dk idi (p<0.05). Sağlıklı bireylerin ortalama yürüme oksijen maliyetleri 0.14±0.02 mL/kg/m, hasta grupta ise 0.18±0.04 mL/kg/m idi (p<0.05). Grup 2de İK anket skoru ile oksijen maliyeti, tercih edilen yürüme hızı, klodikasyon ağrı skalası skoru ve Borg skoru arasında ilişki yoktu. Yürüme oksijen maliyeti ile maksimum yürüme mesafesi (MYM) arasında anlamlı ilişki vardı (p<0.05). Klodikasyon mesafesinin, Borg skoru ve klodikasyon ağrı skalası skoru ile anlamlı ilişkisi vardı. So­nuç: Periferik damar hastalığı olan hastalarda, yürümenin metabolik etkinliği ve tercih edilen yürüme hızı azalabilir. Bu çalışma yürüme oksijen maliyetinin, tercih edilen yürüme hızının, Borg skorunun, klodikasyon mesafesinin ve MYMnin, İKli hastaların hareket kısıtlılığını izlemek için kullanılabilecek objektif parametreler olduğunu göstermektedir.

🔖

Cite This Article

DAL, U., ERDOĞAN, T., KARACA, M. K., YILMAZ, S. B., SUCU, N. (2022). İntermitan klodikasyonu olan hastalarda yürümenin metabolik etkinliği azalır. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 20 - Sayı: 4, 774–779. https://ajindex.com/articles/424651

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation 1995
  2. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008
  3. CD003748. 3.Crowther RG, Spinks WL, Leicht AS, Quigley F, Golledge J. Relationship between temporal-spatial gait parameters, gait kinematics, walking performance, exercise capacity, and physical activity level in peripheral arterial disease. J Vasc Surg 20 07
  4. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999- 2000. Circulation 2004
  5. Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg 1999
  6. Köksal C, Konukoğlu D, Ercan M, Arslan C, Kazımoğlu K, Bozkurt K. Periferik arter hastalarında lipid peroksidasyonu ve antioksidan kapasite. Turk Gogus Kalp Dama 1999
  7. Myers SA, Johanning JM, Stergiou N, Lynch TG, Longo GM, Pipinos II. Claudication distances and the Walking Impairment Questionnaire best describe the ambulatory limitations in patients with symptomatic peripheral arterial disease. J Vasc Surg 2008
  8. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001
  9. Le Faucheur A, Abraham P, Jaquinandi V, Bouyé P, Saumet JL, Noury-Desvaux B. Measurement of walking distance and speed in patients with peripheral arterial disease: a novel method using a global positioning system. Circulation 20 08
  10. Teixeira-Salmela LF, Nadeau S, Milot MH, Gravel D, Requião LF. Effects of cadence on energy generation and absorption at lower extremity joints during gait. Clin Biomech (Bristol, Avon) 2008
  11. Waters RL, Mulroy S. The energy expenditure of normal and pathologic gait. Gait Posture 1999
  12. Tervo RC, Azuma S, Stout J, Novacheck T. Correlation between physical functioning and gait measures in children with cerebral palsy. Dev Med Child Neurol 2002
  13. Chong PF, Garratt AM, Golledge J, Greenhalgh RM, Davies AH. The intermittent claudication questionnaire: a patient- assessed condition-specific health outcome measure. J Vasc Surg 2002
  14. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports E